JP2012502954A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502954A5 JP2012502954A5 JP2011527326A JP2011527326A JP2012502954A5 JP 2012502954 A5 JP2012502954 A5 JP 2012502954A5 JP 2011527326 A JP2011527326 A JP 2011527326A JP 2011527326 A JP2011527326 A JP 2011527326A JP 2012502954 A5 JP2012502954 A5 JP 2012502954A5
- Authority
- JP
- Japan
- Prior art keywords
- acid ceramidase
- cancer
- composition
- composition according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 19
- 102000006772 Acid Ceramidase Human genes 0.000 claims 12
- 108020005296 Acid Ceramidase Proteins 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 239000000523 sample Substances 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 229940121737 Choline kinase inhibitor Drugs 0.000 claims 3
- 102000009058 Death Domain Receptors Human genes 0.000 claims 3
- 108010049207 Death Domain Receptors Proteins 0.000 claims 3
- 229940100198 alkylating agent Drugs 0.000 claims 3
- 239000002168 alkylating agent Substances 0.000 claims 3
- 230000000340 anti-metabolite Effects 0.000 claims 3
- 229940100197 antimetabolite Drugs 0.000 claims 3
- 239000002256 antimetabolite Substances 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000030833 cell death Effects 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 239000013074 reference sample Substances 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 102000002745 Choline Kinase Human genes 0.000 claims 1
- 108010018888 Choline kinase Proteins 0.000 claims 1
- 102100031065 Choline kinase alpha Human genes 0.000 claims 1
- 101710106334 Choline kinase alpha Proteins 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000011284 combination treatment Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- -1 small molecule compound Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08380270 | 2008-09-17 | ||
| EP08380270.2 | 2008-09-17 | ||
| PCT/EP2009/062078 WO2010031825A2 (en) | 2008-09-17 | 2009-09-17 | Methods and compositions for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012502954A JP2012502954A (ja) | 2012-02-02 |
| JP2012502954A5 true JP2012502954A5 (enExample) | 2012-10-25 |
Family
ID=40364454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011527326A Pending JP2012502954A (ja) | 2008-09-17 | 2009-09-17 | 癌治療のための方法および組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20100068302A1 (enExample) |
| EP (1) | EP2340042B1 (enExample) |
| JP (1) | JP2012502954A (enExample) |
| KR (1) | KR20110067041A (enExample) |
| CN (1) | CN102215872B (enExample) |
| AU (1) | AU2009294618A1 (enExample) |
| BR (1) | BRPI0919238A2 (enExample) |
| CA (1) | CA2737551A1 (enExample) |
| DK (1) | DK2340042T3 (enExample) |
| ES (1) | ES2527361T3 (enExample) |
| MX (1) | MX2011002956A (enExample) |
| PL (1) | PL2340042T3 (enExample) |
| PT (1) | PT2340042E (enExample) |
| RU (1) | RU2011143520A (enExample) |
| WO (1) | WO2010031825A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889127B2 (en) | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
| WO2012051415A2 (en) * | 2010-10-13 | 2012-04-19 | Mount Sinai School Of Medicine | Inhibitors of acid ceramidase and uses thereof in cancer and other disease treatment therapies |
| EP2468259A1 (en) * | 2010-12-23 | 2012-06-27 | Traslational Cancer Drugs Pharma, S.L. | Pharmaceutical compositions of pyridinium and quinolinium derivatives |
| KR20140047664A (ko) | 2011-06-20 | 2014-04-22 | 트래스래셔널 캔서 드럭스 파마 에스.엘. | 암에 걸린 대상자에 있어서 화학요법에 대한 임상반응의 예측 방법 |
| EP3741384A1 (en) | 2011-09-07 | 2020-11-25 | Mount Sinai School Of Medicine | Ceramidase and cell differentiation |
| CN109529028A (zh) | 2012-06-01 | 2019-03-29 | 西奈山伊坎医学院 | 在感染的治疗和预防中的神经酰胺水平 |
| SG10201610869TA (en) | 2012-06-26 | 2017-02-27 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti |
| US11813338B2 (en) | 2013-03-12 | 2023-11-14 | The Trustees Of The University Of Pennsylvania | Diagnosing and treating cancer |
| WO2014160390A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Therapeutic acid ceramidase compositions and methods of making and using them |
| EP2983674A4 (en) | 2013-04-08 | 2017-05-10 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| KR101537030B1 (ko) * | 2013-08-23 | 2015-07-16 | (주)바이오디펜스 | 천적동물의 눈을 포함한 홀로그램을 이용한 농작물 보호방법 및 그 보호기구 |
| WO2015028662A1 (en) | 2013-08-30 | 2015-03-05 | Consejo Superior De Investigaciones Cientificas (Csic) | Compositions and methods for characterization and amelioration of rheumatoid arthritis |
| US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
| US11007251B2 (en) | 2015-12-17 | 2021-05-18 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| AU2017248264B2 (en) | 2016-04-07 | 2020-01-30 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
| CN107362370B (zh) * | 2016-05-13 | 2022-07-26 | 国家纳米科学中心 | 一种基于金纳米簇联合NGF siRNA治疗胰腺癌的方法 |
| CN109744199A (zh) * | 2017-11-08 | 2019-05-14 | 南京艾莫瑞生物科技有限公司 | 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用 |
| US12458659B2 (en) * | 2019-02-06 | 2025-11-04 | The Regents Of The University Of California | Methods for treating macrophage-mediated diseases, and methods of identifying agents useful therefore |
| US20220362254A1 (en) * | 2019-08-22 | 2022-11-17 | Thomas Jefferson University | Methods for reprogramming cancer cells |
| JP7594358B2 (ja) * | 2019-11-29 | 2024-12-04 | 株式会社ダイセル | エクソソーム産生促進剤 |
| CN114644626A (zh) * | 2020-12-18 | 2022-06-21 | 南京施江医药科技有限公司 | 一种苯环类化合物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830916A (en) * | 1996-05-23 | 1998-11-03 | Duke University | Inhibitor of ceramidase |
| ES2117950B1 (es) * | 1996-08-02 | 1999-09-16 | Univ Granada | Nuevos compuestos que bloquean la biosintesis de fosforilcolina y su uso como segundo mensajero en proliferacion celular. |
| US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| GB0121285D0 (en) * | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| ES2237332B1 (es) * | 2004-01-14 | 2006-11-01 | Consejo Sup. Investig. Cientificas | Derivados de piridinio y quinolinio. |
| RU2006146612A (ru) * | 2004-06-03 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr) |
| KR101322705B1 (ko) * | 2005-04-13 | 2013-10-29 | 꼰세호 수페리올 인베스띠가시오네스 시엔띠피까스 | 콜린 키나아제 베타를 유도하는 의약 조성물 |
| ES2277568B1 (es) * | 2005-12-30 | 2008-04-01 | Consejo Superior De Investigaciones Cientificas | Derivados de triterpenoquinona y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias. |
-
2008
- 2008-12-08 US US12/330,190 patent/US20100068302A1/en not_active Abandoned
-
2009
- 2009-09-17 EP EP09783138.2A patent/EP2340042B1/en active Active
- 2009-09-17 US US13/119,488 patent/US20110256241A1/en not_active Abandoned
- 2009-09-17 CA CA2737551A patent/CA2737551A1/en not_active Abandoned
- 2009-09-17 BR BRPI0919238-7A patent/BRPI0919238A2/pt not_active IP Right Cessation
- 2009-09-17 RU RU2011143520/15A patent/RU2011143520A/ru not_active Application Discontinuation
- 2009-09-17 CN CN200980145259.2A patent/CN102215872B/zh not_active Expired - Fee Related
- 2009-09-17 AU AU2009294618A patent/AU2009294618A1/en not_active Abandoned
- 2009-09-17 PT PT97831382T patent/PT2340042E/pt unknown
- 2009-09-17 ES ES09783138.2T patent/ES2527361T3/es active Active
- 2009-09-17 WO PCT/EP2009/062078 patent/WO2010031825A2/en not_active Ceased
- 2009-09-17 PL PL09783138T patent/PL2340042T3/pl unknown
- 2009-09-17 JP JP2011527326A patent/JP2012502954A/ja active Pending
- 2009-09-17 KR KR1020117008842A patent/KR20110067041A/ko not_active Ceased
- 2009-09-17 DK DK09783138.2T patent/DK2340042T3/da active
- 2009-09-17 MX MX2011002956A patent/MX2011002956A/es active IP Right Grant
-
2011
- 2011-08-12 US US13/209,220 patent/US20120040021A1/en not_active Abandoned
-
2015
- 2015-01-12 US US14/594,860 patent/US20150297576A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011143520A (ru) | Способы и композиции для лечения злокачественных опухолей | |
| Beatty et al. | The biological underpinnings of therapeutic resistance in pancreatic cancer | |
| Yau | Precision treatment in colorectal cancer: Now and the future | |
| Puzanov et al. | Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression | |
| Pfeffer et al. | A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands | |
| Guo et al. | Cellular mechanism of gene mutations and potential therapeutic targets in ovarian cancer | |
| von Euw et al. | Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines | |
| Felger et al. | Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations | |
| Harmon et al. | Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma | |
| Fisher et al. | Cancer heterogeneity: implications for targeted therapeutics | |
| Björklund et al. | Precision medicine in pheochromocytoma and paraganglioma: current and future concepts | |
| JP6750069B2 (ja) | 癌の分類および使用法 | |
| US20220056541A1 (en) | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer | |
| RS67610B1 (sr) | Kombinacije lsd1 inhibitora za upotrebu u lečenju neoplastičnih bolesti | |
| JP2018508469A5 (enExample) | ||
| Friedman et al. | Landscape of targeted anti-cancer drug synergies in melanoma identifies a novel BRAF-VEGFR/PDGFR combination treatment | |
| Freeman et al. | Effect of perioperative lidocaine and cisplatin on metastasis in a murine model of breast cancer surgery | |
| Park et al. | Survival benefit of pemetrexed in lung adenocarcinoma patients with anaplastic lymphoma kinase gene rearrangements | |
| US8426418B2 (en) | Method to treat melanoma in BRAF inhibitor-resistant subjects | |
| JP2016520528A5 (enExample) | ||
| TW201414475A (zh) | 使用馬賽替尼治療以預測因子所識別的癌症患者亞群 | |
| Antonello et al. | Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAFV600E or wild-type BRAF | |
| Huang et al. | SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer | |
| Yoo et al. | Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma | |
| ES2702038T3 (es) | Métodos de tratamiento de fibrosis y cánceres |